Fourth-quarter biotech job picture

Michael Francisco
I n the final quarter of 2013, the number of advertised biotechnology and pharmaceutical sector jobs rose slightly in two of the three job databases tracked by Nature Biotechnology (Tables 1 and 2) . Compared with the third quarter (Nat. Biotechnol. 31, 1053, 2013) , listings on LinkedIn rose slightly and were mixed on Monster.
GlaxoSmithKline said it will invest £85 million ($137.2 million) in a new manufacturing facility in India, creating 250 jobs. The facility is scheduled to open in 2017; however, a final site has not been determined. GSK also announced a £25 million ($40.5 million) investment to expand its manufacturing site in Montrose, Scotland, part of a £530 million ($859.2 million) spend announced in 2012 to boost UK manufacturing.
Several companies announced large job cuts in the fourth quarter. Merck announced it would cut 8,500 employees in addition to the 7,500-job Michael Francisco is a Senior Editor at Nature Biotechnology. 
Amarin~55
Reduced headcount by 50% to reduce operating expenses after an FDA advisory committee decided against a label expansion for its Vascepa icosapent ethyl.
Ariad 160
Will reduce its US headcount by 40% and temporarily suspended marketing and distribution of leukemia drug Iclusig (ponatinib) owing to reports of risk for arterial thrombotic events.
Boston Scientific 1,100-1,500
Will reduce headcount worldwide to improve operational efficiency and support growth investments. Will transfer select device manufacturing operations from its facilities in Fremont and San Jose, California, to a facility in Costa Rica.
Eisai~130
Will restructure and reduce headcount in the US and EU, consolidating small-molecule process development in Japan and India and ceasing related functions at its site in Andover, Massaschusetts.
Sangart 76
Ceased operations by the end of the year after it was unable to secure another source of funding. In 2013, Sangart's lead compound MP40X missed the primary endpoint in a phase IIb trial to treat lactic acidosis caused by hemorrhagic shock.
Life Sciences 100
Roche's high-throughput DNA sequencing subsidiary will reduce headcount over the next three years before phasing out its product line in mid-2016. Roche said it would establish a dedicated sequencing unit to manage the company's sequencing business.
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